SCHEMBL19974941

SCHEMBL19974941

CC(NC(=O)c1ccc(Cl)cc1)C(O)C(=O)NCC1CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
ALDH1A1 P00352 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
HTT P42858 1/20 0.46
MAPK14 Q16539 2/20 0.46
F10 P00742 3/20 0.45
PRSS1 P07477 3/20 0.45
P2RX7 Q99572 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
P2RX3 P56373 1/20 0.44
CXCR3 P49682 1/20 0.43
ACACB O00763 1/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
KCNH2 Q12809 1/20 0.41
CACNA1I Q9P0X4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975144 0.89 MAPK14 (0.49) ALDH1A1SMN1; SMN2RAB9ANPC1MAPK14
SCHEMBL19975135 0.88 CTSL (0.52) ALDH1A1SMN1; SMN2NPC1MAPK14F10
SCHEMBL19975275 0.87 F10 (0.47) ALDH1A1SMN1; SMN2MAPK14F10PRSS1
SCHEMBL19975064 0.86 F10 (0.53) POLBALDH1A1RAB9ANPC1F10
SCHEMBL28315914 0.85 F10 (0.47) ALDH1A1MAPK14F10PRSS1ACACB
SCHEMBL19975354 0.82 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2MAPK14F10PRSS1
SCHEMBL19974729 0.82 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2MAPK14F10PRSS1
SCHEMBL21183512 0.81 P2RX7 (0.43) POLBALDH1A1RAB9ANPC1F10
SCHEMBL21176167 0.81 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL19974926 0.81 SMN1; SMN2 (0.47) POLBALDH1A1SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C POLB 833/4885ALDH1A1 2271/4885SMN1; SMN2 706/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C POLB 617/4885ALDH1A1 2673/4885SMN1; SMN2 1086/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C POLB 833/4885ALDH1A1 2271/4885SMN1; SMN2 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.